Peptide therapy TikTok claims fact-checked: what's real

What did @taylorreidcoachin actually say?

The creator described personal experience with a peptide, almost certainly PT-141 (bremelanotide), saying it gets you "into the arousal phase very quickly," helps with blood circulation, and increased "natural lubrication" for her personally. She also disclosed she is on bioidentical hormone replacement therapy, taking progesterone and testosterone, which she says keeps her at an "optimal level." That disclosure matters, and we will come back to it.

This is an anecdotal self-report, not a clinical recommendation. She is not prescribing dosages or claiming a cure for any condition. The claims are experience-based, which is both the strength and the limitation of what she is offering here.

Does the science back this up?

On the core claim, yes, more than you might expect from a TikTok testimonial. PT-141 is the peptide almost certainly being discussed, and it is actually FDA-approved. Bremelanotide (Vyleesi) received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women. That approval is not nothing.

The mechanism is real. PT-141 is a melanocortin receptor agonist, acting on MC3R and MC4R receptors in the central nervous system to drive desire and arousal, rather than acting peripherally on blood vessels the way PDE5 inhibitors do. A randomized controlled trial by Clayton et al. (2016, Journal of Sexual Medicine) showed statistically significant improvements in desire and a reduction in distress related to low libido. Regarding lubrication specifically, a study by Portman et al. (2019, Obstetrics and Gynecology) found improvements in arousal-related physiological responses, which would include lubrication as a downstream effect of increased arousal rather than a direct pharmacological action on glands.

What did they get wrong (or right)?

The creator deserves credit for one thing most peptide influencers skip entirely: she acknowledged her hormone replacement therapy context. This is not a minor detail. Testosterone therapy in women has its own evidence base for improving sexual desire and function. A Cochrane review by Islam et al. (2019) found testosterone improved sexual function across multiple domains in women. So when she reports better lubrication and arousal, it is genuinely impossible to attribute that solely to PT-141. The combination effect is plausible but not disentangled here.

The claim that it "helps with blood circulation" is where things get murkier. PT-141 does cause some transient increases in blood pressure, not the kind of vasodilation story people usually tell about circulation-enhancing supplements. The FDA label actually flags transient hypertension as a known side effect. Framing this as a circulation benefit is at minimum imprecise and at worst misleading about the risk profile.

What should you actually know?

PT-141 is one of the few peptides discussed in this category that has actual FDA approval, which puts it in a different category than most of what gets promoted under the peptide therapy umbrella. That approval is specific to premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not a blanket approval for anyone who wants better sex.

Side effects documented in trials include nausea, flushing, and transient blood pressure elevation. The Portman et al. 2019 trial reported nausea in roughly 40 percent of participants. That is a meaningful number that does not come up in most social media testimonials.

• PT-141 sold outside a licensed provider is compounded, not FDA-approved Vyleesi. These are not the same product and should not be treated as equivalent.
• If you are on hormone therapy like this creator, your baseline is already pharmacologically altered. What works for her may not work for you, and attributing outcomes to one agent when you are taking multiple is genuinely difficult even for clinicians.
• Anyone considering this should have a conversation with a licensed provider, not a comment section.

The bottom line

This video is a personal account, not medical advice, and the creator mostly stays in her lane. The core mechanism she is describing, PT-141 supporting arousal response, is backed by real clinical data. The circulation framing is loose and could be cleaned up. The bigger issue is context: her hormone therapy almost certainly contributes to her results, and that nuance gets lost when someone watches this cold and thinks a single peptide will replicate her experience.